CAJ | 학술논문

目的：观察白蛋白结合型紫杉醇治疗晚期转移性乳腺癌的近期疗效和毒副作用。方法24例患者接受含白蛋白结合型紫杉醇方案化疗，每21天为1周期，共2～4个周期。结果24例患者中完全缓解(CR)1例(4.17%)，部分缓解(PR)13例(54.17%)，疾病稳定(SD)3例(12.5%)，疾病进展(PD)7例(29.17%)，有效率（RR）为58.33%(14/24)，疾病控制率（DCR）为70.83%(17/24)。毒副作用主要为Ⅲ～Ⅳ度中性粒细胞减少，发生率为58.33%。结论白蛋白结合型紫杉醇治疗晚期转移性乳腺癌疗效较好，毒副作用可以耐受。
목적：관찰백단백결합형자삼순치료만기전이성유선암적근기료효화독부작용。방법24례환자접수함백단백결합형자삼순방안화료，매21천위1주기，공2～4개주기。결과24례환자중완전완해(CR)1례(4.17%)，부분완해(PR)13례(54.17%)，질병은정(SD)3례(12.5%)，질병진전(PD)7례(29.17%)，유효솔（RR）위58.33%(14/24)，질병공제솔（DCR）위70.83%(17/24)。독부작용주요위Ⅲ～Ⅳ도중성립세포감소，발생솔위58.33%。결론백단백결합형자삼순치료만기전이성유선암료효교호，독부작용가이내수。
Objective To evaluate the effectiveness and safety of albumin-bound paclitaxel in the treatment of patients with metastatic breast cancer.Methods Twenty-four patients with malignant tumors were treated by 2-4 cycles of chemotherapy of weekly albumin-bound paclitaxel and other chemotherapy drugs. Results Among 24 patients, one (4.17%) and thirteen (54.17%) patients had complete and partial response respectively, three (12.50%) disease remained stable and seven(29.17%) disease progressed. The overal response rate was 58.33% (14/24) and the disease control rate was 70.83% (17/24). Neutropenia was the commonest toxicity 58.33% (of grades 3 and 4 neutropenia). Conclusion The albumin-bound paclitaxel has good effectiveness in treating metastatic breast cancer and the side effects could be wel tolerated.